Related Experiment Video
Updated: Jun 21, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
DDR2/STAT3 Positive Feedback Loop Mediates the Immunosuppressive Microenvironment by Upregulating PD-L1 and
Wenfeng Liu1, Feng Zhang2, Bing Quan2
1Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China; Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
Background And Aims:
Transcriptome sequencing revealed high expression of DDR2 in oxaliplatin-resistant hepatocellular carcinoma (HCC). This study aimed to explore the role of DDR2 in oxaliplatin resistance and immune evasion in HCC.
Methods:
Oxaliplatin-resistant HCC cell lines were established. The interaction between DDR2 and STAT3 was investigated, along with the mechanisms involved in DDR2/STAT3-mediated PD-L1 upregulation and polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) accumulation both in vitro and in vivo.
Results:
DDR2 was found to induce the phosphorylation of STAT3, leading to its nuclear translocation. Conversely, the activation of STAT3 enhanced DDR2 expression. A positive feedback loop involving DDR2/STAT3 was identified in oxaliplatin-resistant HCC, which was associated with PD-L1 upregulation and PMN-MDSCs accumulation. Knockdown of DDR2 and STAT3 sensitized oxaliplatin-resistant HCC cells to oxaliplatin and resulted in decreased PMN-MDSCs and increased CD8+ T cells in the tumor microenvironment. Enzyme-linked immunosorbent array and MDSC transwell migration assays indicated that oxaliplatin-resistant HCC cells recruited PMN-MDSCs through CCL20. Dual luciferase reporter assays demonstrated that STAT3 can directly enhance the transcription of PD-L1 and CCL20. Furthermore, treatment with a PD-L1 antibody in combination with CCL20 blockade had significant antitumor effects on oxaliplatin-resistant HCC.
Conclusions:
Our findings revealed a positive feedback mechanism involving DDR2 and STAT3 that mediates the immunosuppressive microenvironment and promotes oxaliplatin resistance and immune evasion via PD-L1 upregulation and PMN-MDSC recruitment. Targeting the DDR2/STAT3 pathway may be a promising therapeutic strategy to overcome immune escape and chemoresistance in HCC.
Insights
A DDR2 and STAT3 feedback loop drives oxaliplatin resistance in liver cancer by promoting immune evasion. Targeting this pathway may overcome chemoresistance and immune escape in hepatocellular carcinoma (HCC).
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- High DDR2 expression is observed in oxaliplatin-resistant hepatocellular carcinoma (HCC).
- DDR2 plays a role in oxaliplatin resistance and immune evasion in HCC.
Purpose of the Study:
- To investigate the role of DDR2 in oxaliplatin resistance in HCC.
- To explore the mechanisms of DDR2-mediated immune evasion in HCC.
Main Methods:
- Established oxaliplatin-resistant HCC cell lines.
- Investigated DDR2 and STAT3 interaction and DDR2/STAT3-mediated PD-L1 upregulation and PMN-MDSC accumulation in vitro and in vivo.
- Analyzed DDR2/STAT3 feedback loop, PD-L1 and CCL20 transcription, and therapeutic effects of PD-L1 antibody and CCL20 blockade.
Main Results:
- A DDR2/STAT3 positive feedback loop was identified in oxaliplatin-resistant HCC, promoting PD-L1 upregulation and PMN-MDSC accumulation.
- Knockdown of DDR2/STAT3 sensitized cells to oxaliplatin, reduced PMN-MDSCs, and increased CD8+ T cells.
- HCC cells recruited PMN-MDSCs via CCL20, and STAT3 directly enhanced PD-L1 and CCL20 transcription.
Conclusions:
- The DDR2/STAT3 pathway mediates an immunosuppressive microenvironment, promoting oxaliplatin resistance and immune evasion.
- Targeting the DDR2/STAT3 pathway offers a potential therapeutic strategy for HCC chemoresistance and immune escape.
More Related Videos
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019